Research programme: anticancer antibodies - Viventia/Affitech

Drug Profile

Research programme: anticancer antibodies - Viventia/Affitech

Latest Information Update: 03 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affitech AS; Viventia Biotech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Feb 2008 Preclinical development is ongoing
  • 17 Aug 2005 BIO-2005 review
  • 03 Feb 2005 Affitech has achieved a research milestone in the discovery and selection of several antibodies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top